The pathological roles of intrinsically disordered proteins in lysosomal acidification dysfunction in neurodegenerative diseases.
6 affiliations
- 1Department of Biology, Syracuse University, Syracuse, NY, 13244, USA.
- 2Interdisciplinary Neuroscience Program, Syracuse University, Syracuse, NY, 13244, USA.
- 3School of Biological Sciences, Nanyang Technological University, Singapore, Singapore, 637551, Singapore.
- 4Department of Biomedical and Chemical Engineering, Syracuse University, Syracuse, NY, 13244, USA.
- 5Department of Biology, Syracuse University, Syracuse, NY, 13244, USA. [email protected].
- 6Interdisciplinary Neuroscience Program, Syracuse University, Syracuse, NY, 13244, USA. [email protected].
Abstract
Neurodegenerative diseases such as Alzheimer's disease (AD), frontotemporal dementia (FTD), and Parkinson's disease (PD) are characterized by the accumulation of intrinsically disordered proteins (IDPs), including amyloid-β (Aβ), tau, and α-synuclein (αSyn). These proteins disrupt neuronal homeostasis through toxic aggregation, impaired proteostasis, and progressive neurodegeneration, in part via dysfunction of the autophagy-lysosomal pathway (ALP). A central feature of this impairment is defective vacuolar-type (H⁺)-ATPase (V-ATPase) function, leading to lysosomal deacidification and reduced degradative capacity. Pathological IDP species converge on V-ATPase through direct interactions with its subunits or by perturbing its assembly, while also exerting protein-specific effects, including lysosomal membrane destabilization, impaired hydrolase activity, and disrupted endolysosomal trafficking. These combined mechanisms create a reciprocal relationship between lysosomal dysfunction and IDP accumulation, in which impaired lysosomal degradation further promotes the persistence and aggregation of pathological IDP species. This review synthesizes current insights into the molecular interplay between IDPs and lysosomal acidification across AD, FTD, and PD, and highlights how these processes contribute to disease progression. We further discuss emerging therapeutic strategies aimed at restoring lysosomal function. These findings underscore lysosomal dysfunction as a common feature of IDP-driven neurodegeneration and a potential therapeutic target across these disorders.
Related
- Nanomaterial modulation of lysosomal homeostasis in neurodegenerative proteinopathies: from pathological-protein degradation to re-release and seeding
- Single-Cell Dissection of Microglial Dysfunction in Diabetes-Associated Neurodegenerative Vulnerability.
- Prometheus’s Fire, Part I: The Flight of Icarus—Molecular Mechanisms Underlying Adipose Tissue Dysfunction in Obesity: From Adaptive Hyperplasia to Pathological Hypertrophy
- ZBED6 deficiency drives pathological cardiac hypertrophy through MEOX1–ERK1/2–dependent autophagy dysfunction
- Insights on the effect of extracellular acidification on an HCN channel: A molecular dynamics study
BibTeX
@article{abdelraouf2026pathological,
title = {{The pathological roles of intrinsically disordered proteins in lysosomal acidification dysfunction in neurodegenerative diseases.}},
author = {Kholoud Abd-ElRaouf and Dylan T Murphy and Lenny Yi Tong Cheong and Jialiu Zeng and Chih Hung Lo},
journal = {Translational neurodegeneration},
year = {2026},
month = oct,
doi = {10.1186/s40035-026-00591-z},
url = {https://europepmc.org/article/MED/42958598},
note = {CC BY},
}
RIS
TY - JOUR
TI - The pathological roles of intrinsically disordered proteins in lysosomal acidification dysfunction in neurodegenerative diseases.
AU - Kholoud Abd-ElRaouf
AU - Dylan T Murphy
AU - Lenny Yi Tong Cheong
AU - Jialiu Zeng
AU - Chih Hung Lo
PY - 2026
DA - 2026/10/28
JO - Translational neurodegeneration
DO - 10.1186/s40035-026-00591-z
UR - https://europepmc.org/article/MED/42958598
AB - Neurodegenerative diseases such as Alzheimer's disease (AD), frontotemporal dementia (FTD), and Parkinson's disease (PD) are characterized by the accumulation of intrinsically disordered proteins (IDPs), including amyloid-β (Aβ), tau, and α-synuclein (αSyn). These proteins disrupt neuronal homeostasis through toxic aggregation, impaired proteostasis, and progressive neurodegeneration, in part via dysfunction of the autophagy-lysosomal pathway (ALP). A central feature of this impairment is defective vacuolar-type (H⁺)-ATPase (V-ATPase) function, leading to lysosomal deacidification and reduced degradative capacity. Pathological IDP species converge on V-ATPase through direct interactions with its subunits or by perturbing its assembly, while also exerting protein-specific effects, including lysosomal membrane destabilization, impaired hydrolase activity, and disrupted endolysosomal trafficking. These combined mechanisms create a reciprocal relationship between lysosomal dysfunction and IDP accumulation, in which impaired lysosomal degradation further promotes the persistence and aggregation of pathological IDP species. This review synthesizes current insights into the molecular interplay between IDPs and lysosomal acidification across AD, FTD, and PD, and highlights how these processes contribute to disease progression. We further discuss emerging therapeutic strategies aimed at restoring lysosomal function. These findings underscore lysosomal dysfunction as a common feature of IDP-driven neurodegeneration and a potential therapeutic target across these disorders.
SN - 2047-9158
ER -